NovoCure Limited (NVCR)
(Delayed Data from NSDQ)
$18.48 USD
-0.64 (-3.32%)
Updated Jul 18, 2024 04:00 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
NovoCure (NVCR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$27.14 | $42.00 | $20.00 | 46.86% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for NovoCure comes to $27.14. The forecasts range from a low of $20.00 to a high of $42.00. The average price target represents an increase of 46.86% from the last closing price of $18.48.
Analyst Price Targets (7 )
Broker Rating
NovoCure currently has an average brokerage recommendation (ABR) of 2.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.14 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, three are Strong Buy, representing 42.86% of all recommendations. A month ago, Strong Buy represented 42.86%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/2/2024 | Evercore Partners | Vijay Kumar | Hold | Hold |
6/3/2024 | Wedbush Securities | David M Nierengarten | Hold | Hold |
5/2/2024 | Piper Sandler | Jason Bednar | Strong Buy | Strong Buy |
4/3/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Strong Buy |
3/12/2024 | H.C. Wainwright & Co. | Emily Bodnar | Hold | Hold |
2/22/2024 | SVB Securities | Jonathan W Chang | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.14 |
ABR (Last week) | 2.14 |
# of Recs in ABR | 7 |
Average Target Price | $27.14 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -0.40 |